Article Text
Abstract
The role of substance P (SP) in physiological haematopoiesis is well established. However, it also seems to be important in the neoplastic transformation of bone marrow, leading to the development of acute leukaemia in children, and also metastases to bone marrow of solid tumours (particularly neuroblastoma and breast cancer) in early stages of these diseases. This review summarises the available data on SP involvement in both processes. In the future, SP antagonists may be used as anti-neoplastic drugs, for example by direct or indirect blocking of tumour cell proliferation through inhibition of growth factor production and interleukin-1b synthesis.
- ALL, acute lymphocytic leukaemia
- BM, bone marrow
- G-CSF, granulocyte colony stimulating factor
- GM-CSF, granulocyte monocyte colony stimulating factor
- HK, haemokinin
- HSC, haematopoietic stem cell
- IL, interleukin
- MSC, mesenchymal stem cell
- NK, neurokinin
- NK-R, neurokinin receptor
- PPT, preprotachykinin
- SCF, stem cell factor
- SP, substance P
- substance P
- tachykinins
- hematopoiesis
- malignancy
Statistics from Altmetric.com
- ALL, acute lymphocytic leukaemia
- BM, bone marrow
- G-CSF, granulocyte colony stimulating factor
- GM-CSF, granulocyte monocyte colony stimulating factor
- HK, haemokinin
- HSC, haematopoietic stem cell
- IL, interleukin
- MSC, mesenchymal stem cell
- NK, neurokinin
- NK-R, neurokinin receptor
- PPT, preprotachykinin
- SCF, stem cell factor
- SP, substance P
Footnotes
-
Published Online First 15 December 2006
-
Competing interests: None.